Skip to main content
Premium Trial:

Request an Annual Quote

Pacific Biosciences Begins Trading on Nasdaq

Premium

This article was originally published Oct. 27.

Pacific Biosciences' registration statement for its initial public offering was declared effective by the Securities and Exchange Commission last week and the company started trading on the Nasdaq Global Select Market on Oct. 27 under the ticker symbol "PACB."

The company raised $200 million in its IPO, offering 12.5 million shares of common stock at $16 per share and granting its underwriters a 30-day option to purchase up to 1.875 million shares at that price to cover over-allotments.

Including over-allotments, the company stands to raise up to $230 million in the offering, or $216 million after underwriting discounts and commissions. This is more than the $200 million the company set out to raise initially (IS 8/24/2010), but less than the $244.4 million maximum aggregate offering price it had proposed last month (IS 10/26/2010).

Following the offering, PacBio has at least 50.1 million shares of common stock outstanding, or almost 52 million if the underwriters exercise their over-allotment option in full.

As of Tuesday mid-day of this week, PacBio's shares traded at approximately $16.50.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.